$1.28 0.06 (+4.92%)
11/6/2009 3:59 PM

Dynavax Technologies Corp (DVAX)

CAPS Rating: 5 out of 5

A biopharmaceutical company that discovers and develops Toll-like Receptor 9 and agonist-based products to treat and prevent infectious diseases, allergies, cancer and chronic inflammatory.

Current Price $1.28 Mkt Cap $52.84M
Open $1.22 P/E Ratio 17.43
Prev. Close $1.22 Div. (Yield) N/A (N/A)
Daily Range $1.20 - $1.29 Volume 386,046
52-Wk Range $0.15 - $3.35 Avg. Daily Vol. 673,000

DVAX News and Commentary

Caps

This ticker is not currently Ratable.

Add Stock to Watchlist

All Members

67 Outperform
5 Underperform
 

All-Star Members

14 Outperform
1 Underperform
 

Wall Street

2 Outperform
0 Underperform
 

Top DVAX Bull/Bear Pitches

The best Bull and Bear pitches based on recency and number of recommendations.

foolphighter (< 20)
Submitted January 12, 2007

Small biotech has recently released promising late stage trial results for its HEPLSAV hepatitus B vaccine drug, as well as encouraging earlier stage results for its TLR9 agonist in cancer indications. The stock took a large hit Jan. 8th when its… More

0 Comments | Reply | Report this Post

Top Bear Pitch

There are no pitches that meet the Top Bear criteria. Explain

If this upsets you, start recommending pitches below!

DVAX VS S&P 500 (SPY)

Recent Community Commentary

Read the most recent pitches from members about DVAX.

Recs

0
Member Avatar wontfindaname (< 20) Submitted: 3/18/2008 5:49:41 PM : Outperform Start Price: $2.46 DVAX Score: -26.73

Expect the huge gap to get filled over the next few days and a slow rise back to 6 over the next couple of months.

Report this Post 0 Comments | Reply | Permalink

Recs

0
Member Avatar uberpaige (< 20) Submitted: 2/26/2007 2:12:23 PM : Outperform Start Price: $5.20 DVAX Score: -53.82

another hope for quick accuracy points.

Report this Post 0 Comments | Reply | Permalink

Recs

2
Member Avatar foolphighter (< 20) Submitted: 1/12/2007 2:11:42 AM : Outperform Start Price: $6.02 DVAX Score: -58.75

Small biotech has recently released promising late stage trial results for its HEPLSAV hepatitus B vaccine drug, as well as encouraging earlier stage results for its TLR9 agonist in cancer indications. The stock took a large hit Jan. 8th when its TOLAMBA allergy drug failed to show therapeutic benefit based on interim analysis, that appears to present a buying opportunity, particularly since the reason for the failure appears to be the lack of clinically significant disease in the study population. Cash of $1.50/share & no debt and the recent filing of a $100M shelf registration suggests the company is well-positioned to leverage its recent progress into further positive developments. the stock appears to offer a reasonable risk/reward after the recent sell-off.

Report this Post 0 Comments | Reply | Permalink
View All 16 Pitches »

Leaderboard

Find the members with the highest scoring picks in DVAX.

Score Leader

kyle42

kyle42 (< 20) Score: +77.69

The Score Leader is the member with the highest score across all their picks in DVAX.

Top
Pick 		Member Name Member
Rating 		Start
Date 		Call Time
Frame 		Start
Price 		Stock
Gain 		S&P
Gain 		Score Commentary
hawkider 59.72 12/8/2006 Underperform 3Y $9.52 -86.55% -19.41% +67.14 1 Comment
mavimadero 88.43 10/9/2006 Underperform 3W $7.29 -82.44% -15.68% +66.76
HondurasAlan 50.12 1/8/2007 Underperform 3W $6.14 -79.15% -19.51% +59.65
Turkmenbashi 48.95 1/8/2007 Underperform NS $5.97 -78.56% -19.45% +59.11
dozer963 < 20 3/18/2008 Underperform NS $2.30 -44.35% -15.00% +29.35
ntch 85.30 3/18/2008 Outperform 5Y $2.15 -40.47% -16.11% -24.36
Weshag < 20 3/18/2008 Outperform NS $2.19 -41.55% -15.82% -25.73
kelloggs33189 < 20 5/5/2008 Outperform 5Y $2.46 -47.97% -21.23% -26.73
Nardonardo123 94.16 5/5/2008 Outperform 5Y $2.46 -47.97% -21.23% -26.73
This player feels very strongly about this pick and has marked it a Top Pick. Top Picks do not affect a player’s score. wontfindaname < 20 5/5/2008 Outperform 3M $2.46 -47.97% -21.23% -26.73 1 Comment
View Complete Scorecard »

Wall Street

See what the Wall Street professionals think, according to their public statements and filings.

Member Name Member
Rating		 Start
Date		 Call Time
Frame		 Start
Price		 Stock
Gain		 S&P
Gain		 Score End Date Commentary
TrackSusquehanna 74.76 9/10/2009 Outperform NS $2.95 -56.61% +3.70% -60.31
TrackZacks 69.52 2/20/2008 Outperform 3M $4.95 -55.56% -4.12% -51.44 3/19/2008 @ $2.20 1 Comment
TrackCreditSuiss 91.16 10/3/2007 Outperform NS $4.50 -71.56% -27.03% -44.53
TrackMerriman < 20 12/20/2006 Outperform NS $9.26 -73.00% -6.41% -66.59 3/18/2008 @ $2.50
TrackJMP < 20 11/30/2006 Outperform NS $9.90 -46.67% +3.87% -50.53 2/26/2007 @ $5.28

Featured Broker Partners